E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
XtalPi’s hair loss drug candidate targets a lactate–autophagy pathway to reactivate quiescent hair follicle stem cells.
imphoenix82
The FDA approval is based on Phase 3 data, with 42% of adolescent patients with severe alopecia areata receiving Olumiant 4 mg achieving at least 80% scalp hair coverage at Week 36, compared with 5% on placebo.
imphoenix82
Hair vaccine: Myth or future therapeutic reality? A new study explores how immune regulation, regenerative medicine and emerging technologies could shape the future of hair-loss treatment.
imphoenix82
AbbVie has received approval from the European Commission (EC) for RINVOQ (upadacitinib; 15 mg and 30 mg, once daily) to treat adults and adolescents aged 12 years and older with severe alopecia areata (AA). Alopecia areata is an autoimmune disorder that causes unpredictable hair loss, ranging from small bald patches on the scalp to complete […]
imphoenix82
The approval enables the introduction of QR678’s patented hair regenerative products in Malaysia and supports its continued expansion across Asia.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
